Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)
Launched by GRUPO ESPANOL DE TUMORES NEUROENDOCRINOS · Feb 14, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The SPAINTRK trial is studying the effects of a medication called Larotrectinib on patients with certain types of cancer known as solid neoplasms that have a specific genetic change called NTRK fusion. This trial aims to gather information about how well Larotrectinib works for these patients in Spain, using data collected from their medical records. Larotrectinib is a new treatment option that has been approved for use in patients with NTRK fusions, and this study will help doctors understand its effectiveness better.
To be part of this study, patients of any age must have a confirmed diagnosis of solid tumors with NTRK fusions and must have received Larotrectinib under a special access program before it was approved for broader use. The trial will include 19 patients from various treatment centers across Spain. Participants will not need to do anything extra, as the information will be gathered from their existing medical records. This research is important because it will provide valuable insights into how well this treatment works for a rare group of cancers, helping doctors choose the best options for their patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Infant and adult patients (all ages).
- • 2. Patients with confirmed diagnosis of solid neoplasms.
- • 3. Patients must have detected NTRK fusions by the following diagnostic methods NGS, fluorescence in situ hybridization (FISH) and/or Immunohistochemistry (IHC).
- • 4. Patients must be treated with Larotrectinib under the compassionate use program (before the commercialization) in order to be included in the study.
- • 5. Data should be available in order to evaluate effectiveness and consequent follow up.
- Exclusion Criteria:
- • 1. Patients with solid neoplasms treated with Larotrectinib in clinical trials or other settings different from clinical practice.
- • 2. Patients that initiated treatment with Larotrectinib after the obtention of prize-reimbursement and commercialization
About Grupo Espanol De Tumores Neuroendocrinos
The Grupo Español de Tumores Neuroendocrinos (GETNE) is a leading Spanish organization dedicated to advancing research, treatment, and education related to neuroendocrine tumors (NETs). Comprising a multidisciplinary network of healthcare professionals, including oncologists, endocrinologists, and researchers, GETNE focuses on improving patient outcomes through collaborative clinical trials, innovative therapeutic strategies, and comprehensive clinical guidelines. The group's commitment to fostering knowledge sharing and promoting best practices in the management of NETs positions it at the forefront of clinical research and patient care in this specialized field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Madrid, , Spain
Barcelona, , Spain
Santander, Cantabria, Spain
Lugo, , Spain
Barcelona, , Spain
Santiago De Compostela, La Coruña, Spain
Las Palmas De Gran Canaria, Las Palmas, Spain
Pamplona, Navarra, Spain
Barakaldo, Bizkaia, Spain
San Sebastian De Los Reyes, Madrid, Spain
Esplugues De Llobregat, Barcelona, Spain
Torrevieja, Alicante, Spain
Palma, Baleres, Spain
Santiago De Compostela, , Spain
Patients applied
Trial Officials
Jorge Hernando Cubero, M.D., Ph.D.
Study Director
Hospital Vall d'Hebron
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported